Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury  by Timmers, Leo et al.
M
c
F
a
‡
M
o
C
w
s
t
s
a
N
i
a
Journal of the American College of Cardiology Vol. 53, No. 6, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
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Objectives This study sought to examine whether exenatide is capable of reducing myocardial infarct size.
Background Exenatide is a glucagon-like peptide (GLP)-1 analogue with insulinotropic and insulinomimetic properties. Be-
cause insulin and GLP-1 have been described as reducing apoptosis, exenatide might confer cardioprotection
after acute myocardial infarction (MI).
Methods Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary ar-
tery ligation and subsequent reperfusion. Infarct size was assessed with Evans Blue (Sigma-Aldrich, St. Louis,
Missouri) and triphenyltetrazolium chloride. Cardiac function was measured with epicardial ultrasound and con-
ductance catheter-based pressure-volume loops. Western blotting, histology, and activity assays were performed
to determine markers of apoptosis/survival and oxidative stress.
Results Exenatide reduced myocardial infarct size (32.7  6.4% vs. 53.6  3.9%; p  0.031) and prevented deterioration of
systolic and diastolic cardiac function (systolic wall thickening: 47.3  6.3% vs. 8.1  1.9%, p  0.001; myocardial
stiffness: 0.12  0.06 mm Hg/ml vs. 0.22  0.07 mm Hg/ml; p  0.004). After exenatide treatment, myocardial
phosphorylated Akt and Bcl-2 expression levels were higher compared with those after PBS treatment, and active
caspase 3 expression was lower. In addition, fewer cells were terminal deoxynucleotidyl transferase biotin-dUTP nick
end labeling-positive. In addition, nuclear oxidative stress as assessed with an 8-hydroxydeoxyguanosine staining was
reduced in the exenatide treatment arm, and superoxide dismutase activity and catalase activity were increased. Se-
rum insulin levels increased after exenatide treatment, without affecting glucose levels.
Conclusions These data identify exenatide as a potentially effective compound to reduce infarct size in adjunction to reperfu-
sion therapy in patients with acute MI. (J Am Coll Cardiol 2009;53:501–10) © 2009 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.033i
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eyocardial infarction (MI) results in irreversible loss of
ardiomyocytes. Restoration of the antegrade coronary flow
rom the *Department of Cardiology and the †Department of Clinical Chemistry
nd Hematology, University of Medical Center Utrecht, Utrecht, the Netherlands;
Department of Cardiology and the §Department of Internal Medicine, Academic
edical Center, Amsterdam, Amsterdam, the Netherlands; Interuniversity Cardi-
logy Institute of the Netherlands, Utrecht, the Netherlands; and the ¶Department of
ardiology, Leiden University Medical Center, Leiden, the Netherlands. This work
as funded by the Netherlands Heart Foundation (NHS), grant 2005T022. This
tudy was supported by the NHS (to. Dr. Timmers) and the Netherlands Organiza-
ion for Scientific Research NWO (to Dr. Hoefer). Dr. de Kleijn is a cofounder of a
mall biotech, but there is no conflict of interest with the study. Dr. DeVries is an
dvisor and on the Speakers’ Bureau for Liraglutide, a GLP-1 analog from Novo
ordisk. Dr. Pasterkamp is a cofounder of a start-up company, Cavadis; however, there
s no conflict of interest related to this study.t
Manuscript received June 23, 2008; revised manuscript received October 20, 2008,
ccepted October 20, 2008.n the infarct-related coronary artery limits myocardial
schemic necrosis and is the cornerstone treatment of
T-segment elevation myocardial infarction (STEMI).
owever, despite adequate reperfusion, most patients still
uffer irreversible myocardial cell loss, which is partly caused
y the reperfusion itself (1). Reperfusion induces several
See page 511
brupt biochemical and metabolic changes, including the
eneration of reactive oxygen species leading to oxidative
tress, intracellular calcium overload, the rapid restoration of
hysiologic pH, and inflammation (2). These changes
ventually interact to accelerate myocardial apoptosis
hrough the opening of the mitochondrial permeability
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cessive loss of myocardial tissue
in patients undergoing early
reperfusion therapy, the develop-
ment of novel therapeutics to
reduce or prevent reperfusion in-
jury is of major importance.
Glucose-insulin-potassium in-
fusion has been postulated to
possess cytoprotective potential
and has been investigated in sev-
eral clinical trials for cardiopro-
tection in patients with STEMI.
Its efficacy is controversial, with
some studies reporting a reduc-
tion in mortality in patients with
acute MI (3–5) and most studies
demonstrating no beneficial ef-
fect (6–8). A better alternative
might be exenatide (exendin-4),
a 39 amino acid peptide origi-
nally derived from the saliva of
the gila monster, a venomous
lizard native to the southwestern
U.S. and northern Mexico. It
mimics human glucagon-like
peptide (GLP)-1, a gut incretin
ormone that is released by the gut in response to nutrient
ntake (9). It exerts insulinotropic and insulinomimetic
roperties via the G-protein–coupled GLP-1 receptor,
hich has also been reported to be expressed in the heart
10,11). The GLP-1 has been shown to be cardioprotective
n a rat model of myocardial ischemia and reperfusion (I/R)
njury (12).
The purpose of this study is to investigate whether
xenatide is capable of reducing myocardial infarct size. To
stablish this, we use a clinically relevant large animal model
f myocardial I/R injury. We hypothesize that exenatide
onfers cardioprotection in this model by reducing myocar-
ial apoptosis, resulting in reduced myocardial infarct size
nd improved cardiac function.
ethods
nimals. All experiments were performed in accordance
ith the “Guide for the Care and Use of Laboratory
nimals” prepared by the Institute of Laboratory Animal
esources and with prior approval by the Animal Experi-
entation Committee of the Faculty of Medicine, Utrecht
niversity, the Netherlands.
tudy design. Eighteen Dalland Landrace pigs (70 to 80
g) were pretreated with clopidogrel 75 mg for 3 days and
miodarone 400 mg for 10 days to prevent thrombotic
omplications and arrhythmias, and the treatment was
ontinued after the surgery. Myocardial I/R injury was
Abbreviations
and Acronyms
AAR  area at risk
ED  end-diastole/diastolic
ES  end-systole/systolic
GLP  glucagon-like
peptide
I/R  ischemia and
reperfusion
LCx  left circumflex
coronary artery
LV  left ventricle
MI  myocardial infarction
OHdG 
hydroxydeoxyguanosine
pAkt  phosphorylated Akt
PBS  phosphate-buffered
saline
STEMI  ST-segment
elevation myocardial
infarction
TUNEL  terminal
deoxynucleotidyl
transferase biotin-dUTP
nick end labelingnduced surgically, under general anesthesia as described treviously (13), by left circumflex coronary artery (LCx)
cclusion for 75 min and subsequent reperfusion for 3 days.
efore ischemia, the animals received 300-mg amiodarone
or 30 min, followed by 100 mg/h during the surgical
rocedure, and 100 IU/kg body weight heparin intrave-
ously. Animals were randomly assigned to exenatide treat-
ent (n  9, 10 g SC and 10 g IV 5 min before the
nset of reperfusion and 10 g twice daily SC—a normal
uman dose— on the following 2 days) or placebo
hosphate-buffered saline (PBS) treatment (n  9) follow-
ng the same treatment regimen. The treatment was initi-
ted just before reperfusion to ensure a systemic concentra-
ion at the beginning of reperfusion. All animals were killed
fter 3 days of reperfusion. Additional pigs (PBS n  4,
xenatide n  4) underwent a sham operational procedure
uring which the suture around the coronary artery was
emoved without closing it. Furthermore, additional pigs
PBS n  4, exenatide n  4) were included for harvesting
yocardial tissue 2 h and 4 h after reperfusion for the
ssessment of molecular pathways involved in myocardial
rotection.
/R injury and operational procedure. During the opera-
ion, electrocardiogram, arterial pressure, and capnogram
ere continuously monitored. After median sternotomy, a
ressure-tipped Millar catheter was inserted through the
pex into the left ventricle (LV) to measure LV pressure.
ardiac output was measured with a transonic flow probe
Transonic Systems Inc., Ithaca, New York), which was
laced around the proximal aorta. Ischemia was induced by
emporary proximal LCx ligation with a 2-0 prolene suture.
eperfusion was established by suture release after 75 min of
schemia.
chocardiography. Short-axis epicardial ultrasound im-
ges (Prosound SSD-5000, 5 MHz probe UST-5280-5,
loka Holding Europe AG, Zug, Switzerland) were ob-
ained before MI, 1 h after reperfusion and 72 h after
eperfusion at the mid-papillary level. Wall thickness of the
nfarct area and LV internal area were measured at end-
iastole (ED) and end-systole (ES). Systolic wall thickening
as calculated as: ({wall thickness [ES]  wall thickness
ED]}/wall thickness [ED])  100%, and fractional area
hortening was calculated as: ({LV internal area [ED] LV
nternal area [ES]}/LV internal area [ED])  100%. In the
erminal experiments, stress tests were performed during
obutamine infusion (5.0 g/kg/min).
ressure-volume loops. Pressure-volume loops were as-
essed with a conductance catheter as described previously
13). In short, LV pressure and volume signals derived from
he conductance catheter were displayed and acquired with
Leycom CFL-512 (CD Leycom, Zoetermeer, the Neth-
rlands). Data were acquired during steady state and during
emporal caval vein occlusion, while ventilation was paused
t end-expiration. Analysis of the pressure-volume loops
as performed with custom software as previously described
14). Systolic function was characterized by LV ejection frac-
ion, dP/dtMAX, and ES elastance, which was determined by
t
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hamber stiffness was quantified by linear regression of the ED
ressure-volume relationship (15).
nfarct size. Infarct size was assessed with Evans Blue
Sigma-Aldrich, St. Louis, Missouri) and triphenyltetrazo-
ium chloride staining as described previously (16). In short,
fter 3 days of reperfusion, the proximal LCx was re-
ccluded at exactly the same location, and Evans Blue
Sigma-Aldrich) (1%) was infused into the remaining cor-
nary arteries, allowing determination of the area at risk
AAR). After excision of the heart, the LV was cut into 5
lices from apex to base and incubated in 1% triphenyltra-
olium chloride (Sigma-Aldrich Chemicals, Zwijndrecht,
he Netherlands) in 37°C Sörensen buffer (13.6 g/l potas-
ium dihydrogen phosphate  14.2 g/l disodium hydrogen
hosphate, pH 7.4) for 15 min to discriminate infarct tissue
rom viable myocardium.
nsulin and glucose levels. Serum insulin was analyzed on
n Immulite 1000 immunochemistry system (Siemens
edical Solutions Diagnostics, Tarrytown, New York), and
lasma glucose was analyzed on a DxC 800 routine chem-
stry system (Beckman Coulter, Brea, California).
estern blotting. Total ribonucleic acid and protein were
solated from frozen tissue biopsies with 1 ml Tripure
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Figure 1 Myocardial Infarct Size
Myocardial infarct size quantification as a percentage of the area at risk (AAR) (A)
n  9; exenatide n  9. Representative pictures after Evans Blue (Sigma-Aldrich)
threatened myocardium, red indicates the noninfarcted area within the area at risksolation Reagent (Boehringer, Mannheim, Germany) as
escribed previously (17). For western blotting, 8 g total
rotein was separated on a 10% sodium dodecyl sulfate
olyacrylamide gel electrophoresis gel, transferred onto a
itrocellulose C membrane (Amersham, Buckinghamshire,
nited Kingdom) and blocked with PBS–0.1% Tween–5%
rotifar (Nutricia, Zoetermeer, the Netherlands). The
embrane was incubated overnight at 4°C with a polyclonal
abbit antibody for phosphorylated Akt 1:400 (Cell Signal-
ng Technology, Beverly, Massachusetts), for active caspase
1:100 (Chemicon, Temecula, California), for Bcl-2
:1,000 (Assay Design, Ann Arbor, Michigan), or for Bax
:1,000 (Assay Design) and subsequently for 1 h at room
emperature with goat–anti-rabbit horseradish peroxidase
:2,000 (DAKO, Glostrup, Denmark). Chemiluminescence
ubstrate (NENk Life Science Products, Boston, Massachu-
etts) was used for detection; the bands were analyzed with
he Gel Doc 1000 system (Biorad, Veenendaal, the
etherlands).
mmunostaining. Tissue samples from the border region
nd remote region were fixated in 4% formalin before being
mbedded in paraffin. The border zone was chosen as the
emi-injured region within 4 mm from the infarct zone.
amples from the LV septum were chosen as remote area.
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s a percentage of the total left ventricle (B). Phosphate-buffered saline (PBS)
phenyltetrazolium chloride staining are shown in C and D. Blue indicates non-
white indicates myocardial infarction.D
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Cardioprotective Properties of Exenatide February 10, 2009:501–10fter antigen retrieval in 10-mmol/l citric acid, the tissue
ections were incubated with 10% normal horse serum for
0 min, mouse–anti-8-hydroxydeoxyguanosine (OHdG)
OXIS international, Foster City, California) 1:20 in
BS containing 0.1% (wt/vol) bovine serum albumin
vernight at 4°C, biotin labeled horse–anti-mouse (Vec-
or Laboratories, Burlingame, California) 1:500 for 1 h,
nd with streptavidin-horseradish peroxidase 1:1,000 for
h. Finally, the sections were incubated with hydrogen
eroxide-diaminobenzidine for 10 min. To assess myocar-
ial apoptosis, a terminal deoxynucleotidyl transferase
iotin-dUTP nick end labeling (TUNEL) was performed
ccording to the manufacturer’s instructions (Roche, Woer-
en, the Netherlands), and eventually the deoxyribonucleic
cid nick ends were visualized with diaminobenzidine. The
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Figure 2 Local and Global Systolic Function
Systolic wall thickening (A) and fractional area shortening (B) measured with
echocardiography before myocardial infarction (solid bars), 1 h after reperfu-
sion (green bars), and 3 days after reperfusion (open bars) in rest and during
dobutamine-induced stress (red bars). *p  0.05 versus baseline; §p  0.01
versus baseline; †p  0.01 versus phosphate-buffered saline (PBS) treatment.iections were then shortly counterstained with hematoxylin
nd eosin to visualize the cells. The amount of 8-OHdG–
ositive nuclei and the amount of TUNEL-positive nuclei
as quantified in 4 randomly picked fields/section with
igital image microscopy software (Analysis, Olympus,
ünster, Germany) at 200 magnification and averaged.
he amount of TUNEL-positive cells was expressed as a
ercentage of the total amount of cells.
xidative stress assay. Superoxide dismutase activity and
atalase activity were measured with activity assay kits accord-
ng to the manufacturers’ protocols (Calbiochem [San Diego,
alifornia] and Cayman Chemical [Ann Arbor, Michigan],
espectively). For both assays, 10-l protein samples were
oaded into the wells, and the values were corrected for the
rotein concentration in the sample afterwards.
ata analysis. All analyses were performed in a blinded
ashion. Statistical analysis was performed with SPSS version
5.0 (SPSS Inc., Chicago, Illinois). Values are presented as
ean SEM. Statistical comparison of infarct size, pressure-
olume loop derived functional parameters, histology, and
rotein expression levels was performed with the Student t test.
emodynamic and echocardiographic functional parameters,
nsulin, and glucose levels were compared with a 2-way analysis
f variance for repeated measurements with Bonferroni post
oc tests. Values of p  0.05 were considered significant.
esults
yocardial infarct size. The AAR size was comparable in
xenatide- and PBS-treated animals (33.6  1.7% vs.
5.5  1.8%, respectively, p  0.402), indicating that the
nitial ischemic injury did not differ between the groups.
xenatide administration before reperfusion significantly
educed myocardial infarct size by 40% compared with PBS
dministration (Fig. 1).
ardiac function. Both local and global cardiac function
ere decreased 1 h after I/R injury. Three days later,
owever, recovery of systolic wall thickening and fractional
rea shortening was increased in animals treated with
xenatide compared with PBS-treated animals (Figs. 2A
nd 2B). Beta1-adrenergic stimulation with dobutamine
ncreased functional improvement to a greater extent in
nimals treated with exenatide compared with animals
reated with PBS. The ED and ES volumes were lower in
xenatide-treated pigs compared with control pigs, indicat-
ng that exenatide prevents acute LV dilation after MI and
aintains contractile performance (Figs. 3A and 3B). Also,
ther global functional parameters, such as LV ejection
raction (Fig. 3C), dP/dtMAX (Fig. 3D, Table 1), and ES
lastance (Fig. 3E) were higher after exenatide treatment. In
ddition, myocardial stiffness was lower (Fig. 3F), indicating
hat diastolic function also improved. Furthermore, the ED
ressure increased significantly in PBS-treated animals but
ot in animals treated with exenatide (Table 1). Heart ratesncreased equally in both groups (Table 1). Exenatide did
n
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Fig. 3, Table 1).
nsulin and glucose levels. In pigs treated with exenatide,
he increase in serum insulin levels 4 h after reperfusion was
ignificantly more pronounced compared with control ani-
als, confirming the insulinotropic properties of exenatide in
igs (Fig. 4A). Plasma glucose levels, however, were similar at
ll times in both groups, suggesting that exenatide treatment
ntails a low risk of hypoglycemia (Fig. 4B). Hypoglycemia
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Figure 3 Pressure-Volume Loop Derived Functional Parameters
End-diastolic volume (A), end-systolic (ES) volume (B), ejection fraction (C), dP/dt
conductance catheter 3 days after sham operation or 3 days after myocardial infa
parameters improved in pigs treated with exenatide. †p  0.05 versus phosphateplasma glucose level3.3 mmol/l or60 mg/dl) occurred in
pig (11%) treated with PBS 4 h after reperfusion and in none
f the pigs treated with exenatide.
poptosis and oxidative stress. Different markers of apop-
osis and survival were assessed at different time points after
eperfusion to elucidate potential protection mechanisms by
xenatide. Two hours after reperfusion, expression of phos-
horylated Akt (pAkt) was increased in myocardial tissue of
nimals that were treated with exenatide compared with
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ion, levels of active caspase 3, an effector caspase that
nduces apoptosis, were lower in treated animals compared
ith control animals (Fig. 5B). Also, expression of anti-
poptotic Bcl-2 and pro-apoptotic Bax were determined.
hereas no differences were observed between treated and
emodynamic Status and LV Function
Table 1 Hemodynamic Status and LV Function
PBS
Baseline Sham
SWT infarct (%) 59.9 4.4 51.0 4.3
SWT septum (%) 46.7 3.4 51.0 10.8 5
LVIA ED (cm2) 16.4 0.5 15.6 0.9 1
LVIA ES (cm2) 8.4 0.2 7.9 0.5 1
FAS (%) 48.9 1.2 48.5 4.6 4
HR (beats/min) 70.0 3.8 65.9 4.0 8
MAP (mm Hg) 89.5 4.5 88.6 7.2 7
CO (l/min) 3.8 0.3 3.2 0.2
EDP (mm Hg) 6.0 0.4 6.3 0.4
dPdtmax (mm Hg/s) 1,145 78 1,367 66 13
dPdtmin (mm Hg/s) 1,050 56 1,076 197 9
ummary of hemodynamic parameters and echocardiographic left ventricular (LV) functional par
days after sham (PBS n  4; exenatide n  4), and 3 days after MI (PBS n  9; exenatide n  9
reatment; p  0.05 versus sham; ¶p  0.05 versus PBS treatment.
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Figure 4 Insulin and Glucose Levels
Serum insulin levels (A) and plasma glucose levels (B) before myocardial
infarction (baseline [bl]), 4 h after reperfusion, and 72 h after reperfusion.
Insulin levels increased 4 h after reperfusion due to exenatide treatment,
whereas glucose levels remained unaffected. *p  0.05 versus bl; §p  0.01
versus bl; †p  0.01 versus phosphate-buffered saline (PBS) treatment.CO  cardiac output; ED  end-diastolic; EDP  end-diastolic pressure; ES  end-systolic; FAS  fracti
ressure; SWT  systolic wall thickening.ontrol animals 2 h and 4 h after reperfusion, Bcl-2
xpression levels and Bcl-2/Bax ratios were higher in
reated animals 72 h after reperfusion (Fig. 5C). Activity
f the antioxidant enzymes superoxide dismutase and
atalase were increased in exenatide-treated animals 72 h
Exenatide
Baseline Sham MI
1.9*† 64.4 4.8 50.6 4.5 47.3 6.3‡§
3.6 50.9 2.2 51.1 8.6 56.1 5.2
0.4 16.6 0.6 15.5 0.3 17.0 0.7
0.4*† 8.6 0.4 7.9 0.3 7.8 0.6§
2.0‡ 47.9 1.9 48.7 1.6 54.2 2.9‡§
2.2*† 62.1 2.2 68.8 3.0 79.6 2.6*
3.9‡ 88.2 4.2 85.2 5.7 77.6 2.5
0.3 3.4 0.1 2.8 0.3 3.1 0.3
1.5* 6.4 0.2 6.6 0.2 7.6 0.6
75 1,189 80 1,267 18 1,611 91*¶
79 1,072 65 1,071 108 1,041 48
s before myocardial infarction (MI) (phosphate-buffered saline [PBS] n  13; exenatide n  13),
0.01 versus baseline; †p  0.01 versus sham; ‡p  0.05 versus baseline; §p  0.01 versus PBS
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Figure 5 Apoptotic Markers
Representative Western blots for myocardial phosphorylated Akt expression
2 h after reperfusion (A), caspase-3 4 h after reperfusion (B), and Bcl-2 72 h
after reperfusion (C) in pigs treated with phosphate-buffered saline (PBS) and
exenatide.MI
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ucleic acid fragmentation as assessed with 8-OHdG
taining and TUNEL assay, respectively, were reduced in
order areas of pigs treated with exenatide compared with
ontrol pigs (Fig. 6). TUNEL positive cells were rarely
ound in the remote area (0.12  0.08% [PBS] vs. 0.10 
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Figure 6 Oxidative Stress and Apoptosis
Immunostaining for 8-hydroxydeoxyguanosine in border areas of phosphate-buffere
pictures of terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TU
C and D, respectively. In E, a TUNEL assay on nonthreatened, remote myocardium
 100 m. B  border area; R  remote area..07% [exenatide]; p  0.849) or in sham-operated pnimals. All molecular and histological data are summa-
ized in Table 2.
iscussion
ardioprotection has been extensively investigated in the
0
10
20
30
40
50
60
70
80
90
p=0.024
%
 p
o
si
it
iv
e
n
u
cl
ei
G
PBS Exenatide
R B R B
e (PBS)-treated animals (A) and exenatide-treated animals (B). Representative
ssays on border areas of animals treated with PBS and exenatide are shown in
monstrated. Quantifications of both stainings are shown in F and G. Scale barsB
D
d salin
NEL) a
is deast 30 years, since the beginning of the reperfusion era.
S
m
p
d
e
w
m
m
a
(
e
t
p
w
m
t
e
I
c
w
s
r
a
m
t
i
r
p
a
o
d
i
d
i
g
a
p
i
t
i
t
i
G
w
c
s
p
E
t
(
w
p
s
t
c
i
w
a
(
p
p
s
e
s
t
m
T
m
P
e
a
a
a
a
i
M
S
e
o its; sup
n 2. p 
508 Timmers et al. JACC Vol. 53, No. 6, 2009
Cardioprotective Properties of Exenatide February 10, 2009:501–10uccessful results have been obtained in numerous experi-
ental studies. However, translation of experimentally
romising results into clinical therapy has proven to be
ifficult (2,18). To date, no compound has proven clinical
fficacy in reducing myocardial infarct size in combination
ith reperfusion therapy. Barriers on the experimental level
ight include the use of non-clinically applicable experi-
ental models (e.g., isolated myocytes, genetically modified
nimals), improper timing of compound administration
before ischemia, during early ischemia), and the lack of
mphasis on clinically relevant end points. To increase
ranslational efficiency, it is mandatory to conduct appro-
riately designed pre-clinical studies in large animal models
ith assessment of clinically relevant end points, such as
ortality, myocardial infarct size, and cardiac function. In
his study, we investigated the cardioprotective properties of
xenatide in a clinically compliant pig model of myocardial
/R injury. To induce a pathological substrate that is
omparable to that of the average patients with acute MI,
e selected a period of 75 min of ischemia, although this is
horter than the average time from onset of ischemia to
eperfusion in patients. In pigs, 75 min of ischemia induces
myocardial infarct of 53.6  3.9% of the AAR. Protective
echanisms such as collateralization, ischemic precondi-
ioning, and residual coronary flow might account for delay
n cardiac cell death during ischemia in patients. Pigs closely
esemble humans with regard to cardiovascular anatomy and
hysiology, the treatment was given just before reperfusion,
reperfusion period of 3 days was allowed before assessment
f infarct size, and clinically relevant end points were
etermined. In this model, exenatide reduced myocardial
nfarct size by 40% and significantly improved systolic and
iastolic cardiac performance. This was associated with
ncreased insulin serum levels without changes in plasma
lucose levels, reduced nuclear oxidative stress, and reduced
poptosis.
Bose et al. (12) have previously shown that GLP-1
rotects the rat heart from I/R injury. However, GLP-1 was
arkers of Apoptosis and Oxidative Stress
Table 2 Markers of Apoptosis and Oxidative Stress
2 h
PBS Exenatide P
TUNEL — —
Caspase 3 771 17 685 24 904
pAkt 66.5 5.9 118.1 11.9† 67.9
Bcl-2 864 300 794 306 839
Bax 19.3 4.7 28.4 7.8 26.3
Bcl-2/Bax 59.8 30.2 47.3 23.6 33.8
SOD 78.6 20.7 70.1 8.8 68.0
Catalase 26.1 6.2 31.1 7.2 25.0
8-OHdG — —
ummary of targets that were determined to assess mediators of cardiomyocyte death and cytop
xenatide n  4), and 72 h (PBS n  9; exenatide n  9) after reperfusion. Terminal deoxynucleo
f cells; caspase 3, pAkt, Bcl-2, and Bcl-2-associated X protein (Bax) are expressed as arbitrary un
mol/ml/min/mg protein; 8-hydroxydeoxyguanosine (8-OHdG) is expressed as positive nuclei/mmnfused during the entire ischemic period, rendering uncer- aainty as to whether GLP-1 reduced reperfusion injury or
schemic injury or both. This complicates clinical transla-
ion, because most patients are referred to the clinic after an
schemic period. In an isolated rat heart model, however,
LP-1 was demonstrated to also exert protective effects
hen administered during reperfusion (19). Clinical appli-
ability of GLP-1 is complicated by its very short half-life of
everal minutes, due to rapid breakdown by dipeptidyl
eptidase IV, which requires continuous infusion of GLP-1.
xenatide is approved by the Food and Drug Administra-
ion for glucose control in patients with type 2 diabetes type
20,21). It has a longer half-life (60 to 90 min) compared
ith GLP-1, due to resistance to degradation by dipeptidyl
eptidase IV, and can be administered subcutaneously in
mall volumes (22). This combination of favorable proper-
ies makes exenatide more attractive for clinical application
ompared with GLP-1 and also compared with glucose-
nsulin-potassium. Importantly, the risk of hypoglycemia,
hich regularly causes problems with other antidiabetic
gents, such as sulphonylureas, is reduced with exenatide
20). Also in our study, hypoglycemia did not develop in
igs treated with exenatide.
Several mechanisms might be responsible for the cardio-
rotective effects of exenatide. First, glucose metabolism is
timulated over fatty acid metabolism, which is more
fficient with respect to oxygen consumption for adeno-
ine triphosphate production (23), and which might
herefore reduce oxygen demand. Second, exenatide
ight reduce myocardial apoptosis and oxidative stress.
he GLP-1 can protect the rat heart from I/R injury,
ediated by the prosurvival kinases PI3K/Akt, p42/44
KA, and P70s6 (12,19). In the present study, myocardial
xpression of pAkt was increased after exenatide treatment
nd expression of active caspase 3 were reduced. Also,
ctivity of the antioxidant enzymes superoxide dismutase
nd catalase were higher in animals treated with exenatide,
nd nuclear oxidative stress was reduced. Alternatively,
ncreased serum levels of insulin, which can directly exert
4 h 72 h
Exenatide PBS Exenatide
— 75.1 6.2 49.4 8.0*
283 14* 32 9 49 10
74.3 22.1 111.1 9.8 114.1 21.7
787 276 276 38 409 24†
17.0 7.6 535 182 483 218
74.9 21.7 0.83 0.21 1.83 0.41*
55.1 11.9 57.1 4.4 82.2 9.4*
18.4 3.6 15.5 2.2 23.0 2.4*
— 5,557 757 2,348 336†
e mechanisms. The markers were determined 2 h (PBS n  4; exenatide n  4), 4 h (PBS n  4;
nsferase biotin-dUTP nick end labeling (TUNEL) is expressed as a percentage of the total amount
eroxide dismutase activity (SOD) activity is expressed as U/min; catalase activity is expressed as
0.05 versus PBS; †p  0.01 versus PBS.BS
—
 16
 4.1
 248
 6.4
 8.0
 6.4
 7.0
—
rotectiv
tidyl tranti-apoptotic effects via the insulin receptor (24–26),
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February 10, 2009:501–10 Cardioprotective Properties of Exenatideight have conferred cytoprotection. The fact that GLP-1
rotects against I/R injury in isolated hearts, however,
uggests the presence of mechanisms independent of circu-
ating insulin (19).
The salvage of myocardial tissue by exenatide was accom-
anied by increased cardiac systolic and diastolic perfor-
ance. After Dobutamine infusion, systolic function in-
reased to a greater extent in treated animals, which likely
eflects a reduced number of irreversibly injured cardiomy-
cytes in these pigs.
Besides preservation of cardiomyocytes, other factors
ould have contributed to enhanced cardiac function.
xidative stress is an important mediator of myocardial
tunning, which refers to sustained functional impair-
ent after ischemia of normally perfused, viable myocar-
ium. Also, inhibition of caspase 3 has been demon-
trated to reduce stunning (27). Stunning can prolong for
ays or even weeks after ischemia and can contribute to
ardiac failure in the acute phase after MI. In a previous
tudy, GLP-1 was demonstrated to reduce stunning in a
og model of brief coronary occlusion and reperfusion
28). We have demonstrated that oxidative stress and
aspase 3 expression were reduced after exenatide treatment,
hich might have alleviated myocardial stunning. Finally,
xenatide induces metabolic changes in the heart as fatty
cid metabolism shifts to carbohydrate metabolism (23),
hich demands less oxygen for adenosine triphosphate
roduction. The GLP-1 infusion improves myocardial con-
ractile performance in a canine model of pacing-induced
ilated cardiomyopathy (29). In a small clinical study with
cute MI and successful reperfusion, GLP-1 infusion im-
roved regional and global LV function (30). These bene-
cial effects contributed to improved metabolic efficiency,
nd data on myocardial infarct size were not available in
hese studies.
We have not been able to investigate the effect of
ommon comorbidities such as hypertension, dyslipidemia,
nd diabetes, which might influence the impact of exenatide
n cardioprotection. Cardioprotective effects of exenatide in
iabetic patients might even be more pronounced, because
yperglycemia is an independent factor associated with a
oor outcome, and glycemic control is associated with a
etter outcome in the setting of acute MI (31–33). The
linical efficacy of exenatide, however, remains to be inves-
igated in the near future.
onclusions
e provide compelling evidence that exenatide confers
trong cardioprotection and improves LV systolic and dia-
tolic function in a clinically relevant large animal model of
/R injury. These data identify exenatide as a promising
ompound for myocardial salvage in patients with STEMI
n combination with reperfusion therapy.cknowledgments
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